Literature DB >> 23794078

Blood concentrations of cefuroxime in cardiopulmonary bypass surgery.

Daphne Bertholee1, Peter G J ter Horst, Michel L Hijmering, Alexander J Spanjersberg, Wobbe Hospes, Bob Wilffert.   

Abstract

OBJECTIVES: Patients with coronary artery bypass graft (CABG) surgery are at risk for severe postoperative infections. Prophylactic cefuroxime may help to reduce this risk, however sufficient concentrations, i.e. above the breakpoint (32 mg/L), are mandatory. The aim of this study is to evaluate the blood concentrations of cefuroxime during and after CABG surgery with cardiopulmonary bypass (CPB) and hypothermia, to determine the concentration of cefuroxime in sternum fluid and to evaluate possible factors of influence.
METHODS: Seventeen patients were enrolled in this study, given 1.5 g cefuroxime at anaesthesia induction and an additional 1.5 g at start CPB. Blood samples were collected at skin incision, start CPB, every 30 min on CPB, end CPB, at wound closure and 1 h after surgery. Cefuroxime concentrations were determined by high performance liquid chromatography.
RESULTS: In 47 % of the patients the cefuroxime concentration was below the breakpoint at some point during the operation and in 59 % of the patients 1 h after surgery. A statistically significant inverse correlation between estimated glomerular filtration rate and plasma cefuroxime concentrations was found (P = 0.034). Cefuroxime levels in the sternum are not significantly different from blood levels from the radial artery catheter, taken at approximately the same time (P = 0.30).
CONCLUSIONS: The current antibiotic regimen used did not maintain cefuroxime concentrations above the breakpoint throughout the operation, suggesting insufficient antibiotic prophylaxis. Further research to other antibiotic regimes is therefore necessary.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23794078     DOI: 10.1007/s11096-013-9810-z

Source DB:  PubMed          Journal:  Int J Clin Pharm


  23 in total

Review 1.  The pharmacokinetics of anesthetic drugs and adjuvants during cardiopulmonary bypass.

Authors:  B Mets
Journal:  Acta Anaesthesiol Scand       Date:  2000-03       Impact factor: 2.105

2.  Evolution of antimicrobial prophylaxis in cardiovascular surgery.

Authors:  I Kriaras; A Michalopoulos; M Turina; S Geroulanos
Journal:  Eur J Cardiothorac Surg       Date:  2000-10       Impact factor: 4.191

Review 3.  Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project.

Authors:  Dale W Bratzler; Peter M Houck
Journal:  Am J Surg       Date:  2005-04       Impact factor: 2.565

4.  Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk function.

Authors:  Anders Viberg; Otto Cars; Mats O Karlsson; Siv Jönsson
Journal:  J Clin Pharmacol       Date:  2008-11       Impact factor: 3.126

Review 5.  Biocompatibility in cardiopulmonary bypass.

Authors:  L C Hsu
Journal:  J Cardiothorac Vasc Anesth       Date:  1997-05       Impact factor: 2.628

6.  Systemic availability of prophylactic cefuroxime in patients submitted to coronary artery bypass grafting with cardiopulmonary bypass.

Authors:  J W L Nascimento; M J C Carmona; T M V Strabelli; J O C Auler; S R C J Santos
Journal:  J Hosp Infect       Date:  2005-04       Impact factor: 3.926

7.  Tissue and plasma concentrations of antibiotic during cardiac surgery with cardiopulmonary bypass--microdialysis study.

Authors:  Marek Pojar; Jiri Mandak; Jana Malakova; Iveta Jokesova
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2008-06       Impact factor: 1.245

8.  Tissue and plasma concentrations of cephuroxime during cardiac surgery in cardiopulmonary bypass--a microdialysis study.

Authors:  J Mand'ák; M Pojar; J Maláková; V Lonsk; V Palicka; P Zivný
Journal:  Perfusion       Date:  2007-03       Impact factor: 1.972

Review 9.  Cefuroxime: antimicrobial activity, Pharmacology, and clinical efficacy.

Authors:  B R Smith; J L LeFrock
Journal:  Ther Drug Monit       Date:  1983-06       Impact factor: 3.681

10.  Postoperative mediastinitis in cardiac surgery - microbiology and pathogenesis.

Authors:  B Gårdlund; C Y Bitkover; J Vaage
Journal:  Eur J Cardiothorac Surg       Date:  2002-05       Impact factor: 4.191

View more
  6 in total

1.  Population Pharmacokinetic Model-Based Evaluation of Standard Dosing Regimens for Cefuroxime Used in Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass.

Authors:  Saeed A Alqahtani; Abdullah S Alsultan; Hussain M Alqattan; Ahmed Eldemerdash; Turki B Albacker
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

2.  Pharmacokinetics of cefuroxime in infants and neonates undergoing cardiac surgery.

Authors:  Ralph Gertler; Michael Gruber; Gunther Wiesner; Stanislas Grassin-Delyle; Saïk Urien; Peter Tassani-Prell; Klaus Martin
Journal:  Br J Clin Pharmacol       Date:  2018-06-15       Impact factor: 4.335

3.  Pharmacokinetic Model for Cefuroxime Dosing during Cardiac Surgery under Cardiopulmonary Bypass.

Authors:  J Lanoiselée; P J Zufferey; S Hodin; N Tamisier; L Gergelé; J C Palao; S Campisi; S Molliex; J Morel; X Delavenne; E Ollier
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

4.  Targeting cefuroxime plasma concentrations during coronary artery bypass graft surgery with cardiopulmonary bypass.

Authors:  Marieke Aalbers; Peter G J ter Horst; Wobbe Hospes; Michel L Hijmering; Alexander J Spanjersberg
Journal:  Int J Clin Pharm       Date:  2015-03-20

5.  Quantification of total and unbound cefuroxime in plasma by ultra-performance liquid chromatography tandem mass spectrometry in a cohort of critically ill patients with hypoalbuminemia and renal failure.

Authors:  Joost J van Raaij; Noortje J D Mabelis; Kimberly N Shudofsky; Sjoerd D Meenks; Jos L M L le Noble; Paddy K C Janssen
Journal:  J Clin Lab Anal       Date:  2019-11-30       Impact factor: 2.352

Review 6.  Antibiotics and ECMO in the Adult Population-Persistent Challenges and Practical Guides.

Authors:  Francisco Gomez; Jesyree Veita; Krzysztof Laudanski
Journal:  Antibiotics (Basel)       Date:  2022-03-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.